0

Close
 
Upcoming Allied Market Research
2023
Pelvic Inflammatory Disease Treatment Market

Pelvic Inflammatory Disease Treatment Market

by Drug Class (Macrolides, Tetracycline, Beta-lactam, Nitroimidazoles, Others), by Route of Administration (Oral, Parenteral, Others), by End User (Hospitals, Specialty Centers, Others) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A11672
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pelvic Inflammatory Disease Treatment Market

Request Now !

Pelvic inflammatory disease is an infection of the female reproductive organs. The pelvis includes the ovaries, cervix, fallopian tubes, and uterus. Different types of bacteria can cause this disease, including some bacteria that cause chlamydia and gonorrhea. The bacteria first enters the vagina causing infection and can move to the pelvic organs. If the infection spreads to the blood, pelvic inflammatory disease can become life-threatening. Antibiotics are generally used to treat this disease; however, in case of rupturing of an abscess the patient might require surgery. Men could be the silent carriers of bacteria, hence, in recurrent cases of pelvic inflammatory disease in a woman, it is suggested for the male partner to undergo treatment simultaneously.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the pelvic inflammatory disease treatment market.

Top Impacting Factors

Rise in awareness of the pelvic inflammatory disease among females is increasing the diagnosis rate of the disease, thereby resulting in an increased number of women getting treated for the same.

Furthermore, the first-line treatment of pelvic inflammatory disease involves the use of oral and intramuscular treatment routes, which is why the adoption rate for these treatments is high. This acts as a key growth driver of the global market.

The population of women between the age of 20–24 years is increasing across the world. This age group is known to be the fertile age group and has an increased risk of developing pelvic inflammatory diseases. Hence, it is one of the factors that is propelling the growth of the pelvic inflammatory disease treatment market.

However, the use of preventative methods and misdiagnosis of the disease can impede the market growth during the forecast period. In addition, the risk of the development of resistant microorganisms strains can come up as a challenge for the growth of the pelvic inflammatory disease treatment market.

Key Market Trends

The tetracycline drugs are anticipated to dominate the pelvic inflammatory disease treatment industry. The growth of this segment can be attributed to rise in tetracycline prescriptions, as the drug has proven efficacy in the treatment of cephalosporin.

Some prominent players in the market such as Mayne Pharma and Pfizer, Inc. are making acquisitions and launching new products to consolidate their market positions across the globe. Some of the companies dominating the market are Perrigo Company Plc, Bristol-Myers Squibb Company, and Mylan NN.

North America is expected to dominate the pelvic inflammatory disease treatment market during the forecast period. This dominance is anticipated due to rise in incidence of menopausal disorders, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, and polycystic ovary syndrome, due to the change in lifestyles and rise in stress among females in the U.S.

Key Benefits of the Report

  • This study presents the analytical depiction of the pelvic inflammatory disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the pelvic inflammatory disease treatment market share.
  • The current market is quantitatively analyzed to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the pelvic inflammatory disease treatment market. .
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Pelvic Inflammatory Disease Treatment Report

  • Which are the leading players active in the pelvic inflammatory disease treatment pelvic inflammatory disease treatment market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the pelvic inflammatory disease treatment market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is pelvic inflammatory disease?
  • What is the pelvic inflammatory disease treatment market prediction in the future?
  • What are the current trends and predicted trends?

 Pelvic Inflammatory Disease Treatment Market Report Highlights

Aspects Details
By Drug Class
  • Macrolides
  • Tetracycline
  • Beta-lactam
  • Nitroimidazoles
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
By End User
  • Hospitals
  • Specialty Centers
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Johnson and Johnson Services Inc, Pfizer Inc., Bristol Myers Squibb Company, Sanofi, Merck & Co., Inc, Janssen Pharmaceuticals, Inc., AstraZeneca, Mayne Pharma Group Limited, Mylan N.V.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. Macrolides

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Tetracycline

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Beta-lactam

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Nitroimidazoles

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Parenteral

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Specialty Centers

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Distribution Channel

    • 7.2. Hospital Pharmacy

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Retail Pharmacy

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Drug Class

      • 8.2.3. Market Size and Forecast, By Route Of Administration

      • 8.2.4. Market Size and Forecast, By End User

      • 8.2.5. Market Size and Forecast, By Distribution Channel

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Pelvic Inflammatory Disease Treatment Market

        • 8.2.7.1. Market Size and Forecast, By Drug Class
        • 8.2.7.2. Market Size and Forecast, By Route Of Administration
        • 8.2.7.3. Market Size and Forecast, By End User
        • 8.2.7.4. Market Size and Forecast, By Distribution Channel

      • 8.2.8. Canada Pelvic Inflammatory Disease Treatment Market

        • 8.2.8.1. Market Size and Forecast, By Drug Class
        • 8.2.8.2. Market Size and Forecast, By Route Of Administration
        • 8.2.8.3. Market Size and Forecast, By End User
        • 8.2.8.4. Market Size and Forecast, By Distribution Channel

      • 8.2.9. Mexico Pelvic Inflammatory Disease Treatment Market

        • 8.2.9.1. Market Size and Forecast, By Drug Class
        • 8.2.9.2. Market Size and Forecast, By Route Of Administration
        • 8.2.9.3. Market Size and Forecast, By End User
        • 8.2.9.4. Market Size and Forecast, By Distribution Channel

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Drug Class

      • 8.3.3. Market Size and Forecast, By Route Of Administration

      • 8.3.4. Market Size and Forecast, By End User

      • 8.3.5. Market Size and Forecast, By Distribution Channel

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Pelvic Inflammatory Disease Treatment Market

        • 8.3.7.1. Market Size and Forecast, By Drug Class
        • 8.3.7.2. Market Size and Forecast, By Route Of Administration
        • 8.3.7.3. Market Size and Forecast, By End User
        • 8.3.7.4. Market Size and Forecast, By Distribution Channel

      • 8.3.8. Germany Pelvic Inflammatory Disease Treatment Market

        • 8.3.8.1. Market Size and Forecast, By Drug Class
        • 8.3.8.2. Market Size and Forecast, By Route Of Administration
        • 8.3.8.3. Market Size and Forecast, By End User
        • 8.3.8.4. Market Size and Forecast, By Distribution Channel

      • 8.3.9. Italy Pelvic Inflammatory Disease Treatment Market

        • 8.3.9.1. Market Size and Forecast, By Drug Class
        • 8.3.9.2. Market Size and Forecast, By Route Of Administration
        • 8.3.9.3. Market Size and Forecast, By End User
        • 8.3.9.4. Market Size and Forecast, By Distribution Channel

      • 8.3.10. Spain Pelvic Inflammatory Disease Treatment Market

        • 8.3.10.1. Market Size and Forecast, By Drug Class
        • 8.3.10.2. Market Size and Forecast, By Route Of Administration
        • 8.3.10.3. Market Size and Forecast, By End User
        • 8.3.10.4. Market Size and Forecast, By Distribution Channel

      • 8.3.11. UK Pelvic Inflammatory Disease Treatment Market

        • 8.3.11.1. Market Size and Forecast, By Drug Class
        • 8.3.11.2. Market Size and Forecast, By Route Of Administration
        • 8.3.11.3. Market Size and Forecast, By End User
        • 8.3.11.4. Market Size and Forecast, By Distribution Channel

      • 8.3.12. Russia Pelvic Inflammatory Disease Treatment Market

        • 8.3.12.1. Market Size and Forecast, By Drug Class
        • 8.3.12.2. Market Size and Forecast, By Route Of Administration
        • 8.3.12.3. Market Size and Forecast, By End User
        • 8.3.12.4. Market Size and Forecast, By Distribution Channel

      • 8.3.13. Rest Of Europe Pelvic Inflammatory Disease Treatment Market

        • 8.3.13.1. Market Size and Forecast, By Drug Class
        • 8.3.13.2. Market Size and Forecast, By Route Of Administration
        • 8.3.13.3. Market Size and Forecast, By End User
        • 8.3.13.4. Market Size and Forecast, By Distribution Channel

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Drug Class

      • 8.4.3. Market Size and Forecast, By Route Of Administration

      • 8.4.4. Market Size and Forecast, By End User

      • 8.4.5. Market Size and Forecast, By Distribution Channel

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Pelvic Inflammatory Disease Treatment Market

        • 8.4.7.1. Market Size and Forecast, By Drug Class
        • 8.4.7.2. Market Size and Forecast, By Route Of Administration
        • 8.4.7.3. Market Size and Forecast, By End User
        • 8.4.7.4. Market Size and Forecast, By Distribution Channel

      • 8.4.8. Japan Pelvic Inflammatory Disease Treatment Market

        • 8.4.8.1. Market Size and Forecast, By Drug Class
        • 8.4.8.2. Market Size and Forecast, By Route Of Administration
        • 8.4.8.3. Market Size and Forecast, By End User
        • 8.4.8.4. Market Size and Forecast, By Distribution Channel

      • 8.4.9. India Pelvic Inflammatory Disease Treatment Market

        • 8.4.9.1. Market Size and Forecast, By Drug Class
        • 8.4.9.2. Market Size and Forecast, By Route Of Administration
        • 8.4.9.3. Market Size and Forecast, By End User
        • 8.4.9.4. Market Size and Forecast, By Distribution Channel

      • 8.4.10. South Korea Pelvic Inflammatory Disease Treatment Market

        • 8.4.10.1. Market Size and Forecast, By Drug Class
        • 8.4.10.2. Market Size and Forecast, By Route Of Administration
        • 8.4.10.3. Market Size and Forecast, By End User
        • 8.4.10.4. Market Size and Forecast, By Distribution Channel

      • 8.4.11. Australia Pelvic Inflammatory Disease Treatment Market

        • 8.4.11.1. Market Size and Forecast, By Drug Class
        • 8.4.11.2. Market Size and Forecast, By Route Of Administration
        • 8.4.11.3. Market Size and Forecast, By End User
        • 8.4.11.4. Market Size and Forecast, By Distribution Channel

      • 8.4.12. Thailand Pelvic Inflammatory Disease Treatment Market

        • 8.4.12.1. Market Size and Forecast, By Drug Class
        • 8.4.12.2. Market Size and Forecast, By Route Of Administration
        • 8.4.12.3. Market Size and Forecast, By End User
        • 8.4.12.4. Market Size and Forecast, By Distribution Channel

      • 8.4.13. Malaysia Pelvic Inflammatory Disease Treatment Market

        • 8.4.13.1. Market Size and Forecast, By Drug Class
        • 8.4.13.2. Market Size and Forecast, By Route Of Administration
        • 8.4.13.3. Market Size and Forecast, By End User
        • 8.4.13.4. Market Size and Forecast, By Distribution Channel

      • 8.4.14. Indonesia Pelvic Inflammatory Disease Treatment Market

        • 8.4.14.1. Market Size and Forecast, By Drug Class
        • 8.4.14.2. Market Size and Forecast, By Route Of Administration
        • 8.4.14.3. Market Size and Forecast, By End User
        • 8.4.14.4. Market Size and Forecast, By Distribution Channel

      • 8.4.15. Rest of Asia Pacific Pelvic Inflammatory Disease Treatment Market

        • 8.4.15.1. Market Size and Forecast, By Drug Class
        • 8.4.15.2. Market Size and Forecast, By Route Of Administration
        • 8.4.15.3. Market Size and Forecast, By End User
        • 8.4.15.4. Market Size and Forecast, By Distribution Channel

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Drug Class

      • 8.5.3. Market Size and Forecast, By Route Of Administration

      • 8.5.4. Market Size and Forecast, By End User

      • 8.5.5. Market Size and Forecast, By Distribution Channel

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Pelvic Inflammatory Disease Treatment Market

        • 8.5.7.1. Market Size and Forecast, By Drug Class
        • 8.5.7.2. Market Size and Forecast, By Route Of Administration
        • 8.5.7.3. Market Size and Forecast, By End User
        • 8.5.7.4. Market Size and Forecast, By Distribution Channel

      • 8.5.8. South Africa Pelvic Inflammatory Disease Treatment Market

        • 8.5.8.1. Market Size and Forecast, By Drug Class
        • 8.5.8.2. Market Size and Forecast, By Route Of Administration
        • 8.5.8.3. Market Size and Forecast, By End User
        • 8.5.8.4. Market Size and Forecast, By Distribution Channel

      • 8.5.9. Saudi Arabia Pelvic Inflammatory Disease Treatment Market

        • 8.5.9.1. Market Size and Forecast, By Drug Class
        • 8.5.9.2. Market Size and Forecast, By Route Of Administration
        • 8.5.9.3. Market Size and Forecast, By End User
        • 8.5.9.4. Market Size and Forecast, By Distribution Channel

      • 8.5.10. UAE Pelvic Inflammatory Disease Treatment Market

        • 8.5.10.1. Market Size and Forecast, By Drug Class
        • 8.5.10.2. Market Size and Forecast, By Route Of Administration
        • 8.5.10.3. Market Size and Forecast, By End User
        • 8.5.10.4. Market Size and Forecast, By Distribution Channel

      • 8.5.11. Argentina Pelvic Inflammatory Disease Treatment Market

        • 8.5.11.1. Market Size and Forecast, By Drug Class
        • 8.5.11.2. Market Size and Forecast, By Route Of Administration
        • 8.5.11.3. Market Size and Forecast, By End User
        • 8.5.11.4. Market Size and Forecast, By Distribution Channel

      • 8.5.12. Rest of LAMEA Pelvic Inflammatory Disease Treatment Market

        • 8.5.12.1. Market Size and Forecast, By Drug Class
        • 8.5.12.2. Market Size and Forecast, By Route Of Administration
        • 8.5.12.3. Market Size and Forecast, By End User
        • 8.5.12.4. Market Size and Forecast, By Distribution Channel

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Mayne Pharma Group Limited

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Pfizer Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. AstraZeneca

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Johnson And Johnson Services Inc

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. F. Hoffmann-La Roche Ltd

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Janssen Pharmaceuticals, Inc.

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Sanofi, Merck And Co., Inc

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Mylan N.V.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Teva Pharmaceutical Industries Ltd

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Bristol Myers Squibb Company

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR MACROLIDES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR TETRACYCLINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR BETA-LACTAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR NITROIMIDAZOLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. U.S. PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 26. U.S. PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. U.S. PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 30. CANADA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. CANADA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. ITALY PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 51. ITALY PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. ITALY PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. ITALY PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. UK PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 59. UK PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. UK PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. UK PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. CHINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 76. CHINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. CHINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. INDIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 84. INDIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. INDIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. INDIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 128. UAE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 129. UAE PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 130. UAE PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. UAE PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA PELVIC INFLAMMATORY DISEASE TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 140. MAYNE PHARMA GROUP LIMITED: KEY EXECUTIVES
  • TABLE 141. MAYNE PHARMA GROUP LIMITED: COMPANY SNAPSHOT
  • TABLE 142. MAYNE PHARMA GROUP LIMITED: OPERATING SEGMENTS
  • TABLE 143. MAYNE PHARMA GROUP LIMITED: PRODUCT PORTFOLIO
  • TABLE 144. MAYNE PHARMA GROUP LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. PFIZER INC.: KEY EXECUTIVES
  • TABLE 146. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 147. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 148. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 149. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 151. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 152. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 153. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 154. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. JOHNSON AND JOHNSON SERVICES INC: KEY EXECUTIVES
  • TABLE 156. JOHNSON AND JOHNSON SERVICES INC: COMPANY SNAPSHOT
  • TABLE 157. JOHNSON AND JOHNSON SERVICES INC: OPERATING SEGMENTS
  • TABLE 158. JOHNSON AND JOHNSON SERVICES INC: PRODUCT PORTFOLIO
  • TABLE 159. JOHNSON AND JOHNSON SERVICES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 161. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 162. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 163. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 164. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 165. JANSSEN PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 166. JANSSEN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 167. JANSSEN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 168. JANSSEN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 169. JANSSEN PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170. SANOFI, MERCK AND CO., INC: KEY EXECUTIVES
  • TABLE 171. SANOFI, MERCK AND CO., INC: COMPANY SNAPSHOT
  • TABLE 172. SANOFI, MERCK AND CO., INC: OPERATING SEGMENTS
  • TABLE 173. SANOFI, MERCK AND CO., INC: PRODUCT PORTFOLIO
  • TABLE 174. SANOFI, MERCK AND CO., INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 176. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 177. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 178. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 179. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 181. TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 182. TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
  • TABLE 183. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 184. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. BRISTOL MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 186. BRISTOL MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 187. BRISTOL MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 188. BRISTOL MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 189. BRISTOL MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PELVIC INFLAMMATORY DISEASE TREATMENT MARKET
  • FIGURE 3. SEGMENTATION PELVIC INFLAMMATORY DISEASE TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PELVIC INFLAMMATORY DISEASE TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPELVIC INFLAMMATORY DISEASE TREATMENT MARKET
  • FIGURE 11. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR MACROLIDES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR TETRACYCLINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR BETA-LACTAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR NITROIMIDAZOLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 18. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 26. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. PELVIC INFLAMMATORY DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: PELVIC INFLAMMATORY DISEASE TREATMENT MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. MAYNE PHARMA GROUP LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. MAYNE PHARMA GROUP LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. MAYNE PHARMA GROUP LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. JOHNSON AND JOHNSON SERVICES INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. JOHNSON AND JOHNSON SERVICES INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. JOHNSON AND JOHNSON SERVICES INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. JANSSEN PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. JANSSEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. JANSSEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. SANOFI, MERCK AND CO., INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. SANOFI, MERCK AND CO., INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. SANOFI, MERCK AND CO., INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. MYLAN N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. MYLAN N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. BRISTOL MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. BRISTOL MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. BRISTOL MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Pelvic Inflammatory Disease Treatment Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers